synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-9054. 19. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992;267:4338-4344. 20. Hamasaki Y, Kitzler J, Hardman R, Nettesheim P, Eling TE. Phor- bol ester and epidermal growth factor enhance the expression of two inducible prostaglandin H synthase genes in rat tracheal epi- thelial cells. Arch Biochem Biophys 1993;304:226-234. 21. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000;30:3-21. 22. Davies RA, Knight B, Tian YW, Yeoh GC, Olynyk JK. Hepatic oval cell response to the choline-deficient, ethionine supplemented model of murine liver injury is attenuated by the administration of a cyclo-oxygenase 2 inhibitor. Carcinogenesis 2006;27:1607- 1616. 23. Marsden ER, Hu Z, Fujio K, Nakatsukasa H, Thorgeirsson SS, Evar- ts RP. Expression of acidic fibroblast growth factor in regenerating liver and during hepatic differentiation. Lab Invest 1992;67:427- 433. 24. Nakamura T, Nawa K, Ichihara A. Partial purification and charac- terization of hepatocyte growth factor from serum of hepatecto- mized rats. Biochem Biophys Res Commun 1984;122:1450-1459. 25. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepato- cyte growth factor is essential for liver development. Nature 1995;373:699-702. 26. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepa- tocyte growth factor receptor as the c-met proto-oncogene prod- uct. Science 1991;251:802-804. 27. Tsukada Y, Miyazawa K, Kitamura N. High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibi- tion of the human hepatocellular carcinoma cell line HepG2. J Biol Chem 2001;276:40968-40976. 28. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma develop- ment. Oncogene 2001;20:8125-8135. 29. Webster CR, Anwer MS. Phosphoinositide 3-kinase, but not mitogen-activated protein kinase, pathway is involved in hepato- cyte growth factor-mediated protection against bile acid-induced apoptosis in cultured rat hepatocytes. Hepatology 2001;33:608- 615. 30. Yin L, Lynch D, Sell S. Participation of different cell types in the restitutive response of the rat liver to periportal injury induced by allyl alcohol. J Hepatol 1999;31:497-507. 31. Pi L, Ding X, Jorgensen M, et al. Connective tissue growth factor with a novel fibronectin binding site promotes cell adhesion and migration during rat oval cell activation. Hepatology 2008;47:996- 1004. 32. Han S, Ritzenthaler JD, Wingerd B, Rivera HN, Roman J. Extra- cellular matrix fibronectin increases prostaglandin E2 receptor Bae SH, et al: Hepatic Oval Cell Proliferation via COX-2 Signaling 375 subtype EP4 in lung carcinoma cells through multiple signaling pathways: the role of AP-2. J Biol Chem 2007;282:7961-7972. 33. Han S, Sidell N, Roser-Page S, Roman J. Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression. Int J Cancer 2004;111:322-331. 34. Parker J, Kaplon MK, Alvarez CJ, Krishnaswamy G. Prostaglandin H synthase expression is variable in human colorectal adenocarci- noma cell lines. Exp Cell Res 1997;236:321-329. 35. Oh SH, Miyazaki M, Kouchi H, et al. Hepatocyte growth fac- tor induces differentiation of adult rat bone marrow cells into a hepatocyte lineage in vitro. Biochem Biophys Res Commun 2000;279:500-504. 36. Sum EY, Shackleton M, Hahm K, et al. Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development. Oncogene 2005;24:4820-4828. 37. Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001;7:1410-1418. 38. Oh SH, Witek RP, Bae SH, et al. Bone marrow-derived hepatic oval cells differentiate into hepatocytes in 2-acetylaminofluorene/ partial hepatectomy-induced liver regeneration. Gastroenterology 2007;132:1077-1087. 39. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci 2003;74:143-153. 40. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prosta- glandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002;62:28-32. 41. Jobin C, Morteau O, Han DS, Balfour Sartor R. Specific NF-kappaB blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology 1998;95:537-543. 42. Lowes KN, Croager EJ, Abraham LJ, Olynyk JK, Yeoh GC. Upregu- lation of lymphotoxin beta expression in liver progenitor (oval) cells in chronic hepatitis C. Gut 2003;52:1327-1332. 43. Okano J, Shiota G, Matsumoto K, et al. Hepatocyte growth factor exerts a proliferative effect on oval cells through the PI3K/AKT signaling pathway. Biochem Biophys Res Commun 2003;309:298- 304. 44. Okabe M, Tsukahara Y, Tanaka M, et al. Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver. Development 2009;136:1951-1960. 45. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carci- nogenesis. Cancer Res 1996;56:4566-4569. 46. Baek JY, Hur W, Wang JS, Bae SH, Yoon SK. Selective COX- 2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest. World J Gastroenterol 2007;13:1175-1181. 47. Baatar D, Jones MK, Pai R, et al. Selective cyclooxygenase-2 blocker delays healing of esophageal ulcers in rats and inhibits ulceration-triggered c-Met/hepatocyte growth factor receptor in-